OBJECTIVE：To evaluate the economics of infliximab in the treatment of ulcerative colitis. METHODS ：Retrieved from CNKI ，Wanfang database ，VIP，PubMed，Embase database and Cochrane Library since Oct. 16th in 2019，randomized controlled trials （RCTs）about infliximab （trial group ）vs. conventional drugs （control group ）in the treatment of ulcerative colitis were collected ，and efficacy and safety of two groups were compared by Meta-analysis. The economics were analyzed by cost-utility analysis ，and single factor sensitivity analysis and probability sensitivity analysis were conducted. RESULTS ：The results of Meta-analysis showed that clinical response rate [RR ＝1.97，95％ CI （1.64，2.36），P＜0.000 01] and clinical remission rate [RR ＝3.19，95％CI（1.83，5.57），P＜0.000 1] in double blind trial subgroup of infliximab treatment were both significantly higher than than control group of conventional treatment. There was no statistical significance in the incidence of severe ADR between 2 groups [RR ＝0.76，95％CI（0.54，1.06），P＝0.10]. The incremental cost-utility ratio of trial group was 348 243.88 yuan/quality-adjusted life-year （QALY），which was significantly higher than the patient ’s willingness to pay threshold （212 676 yuan）.The sensitivity analysis supported above results. CONCLUSIONS ：Under the current level of medical security in China ， compared with conventional therapy ，infliximab is less economical for the treatment of ulcerative colitis.